Study of Motexafin Gadolinium for the Treatment of Non-Hodgkin's Lymphoma

Completed · Phase 2

Conditions studied: Lymphoma, Non-Hodgkin's Lymphoma

In brief

The primary purpose of this study is to find out if motexafin gadolinium may be an effective treatment for patients with non-Hodgkin's lymphoma (NHL). Secondly, the safety and side effects of motexafin gadolinium will be evaluated.

Key facts

Study ID

NCT00086034

Run by

Pharmacyclics LLC.

People needed

35

Last updated by the study team

2007-05-15

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• ≥ 18 years old
• Refractory or relapsed indolent NHL. Eligible WHO histologies include follicular NHL (Grades 1, 2, and 3); marginal zone nodal; marginal zone splenic; and mucosa-associated lymphoid tissue (MALT) types
• Failed ≥ 1 previous regimens, one of which must have contained rituximab as either a single agent or in combination with chemotherapy
• ECOG performance status score either 0 or 1
• Willing and able to provide written informed consent

You may not qualify if…

• Laboratory values of:
• Platelet count < 50,000/µL
• AST or ALT > 2 x the upper limit of normal (ULN)
• Total bilirubin > 2 x ULN
• Creatinine > 2.0 mg/dL
• and
• Greater than three prior regimens (where a regimen is defined as a treatment for NHL given after disease progression)
• Uncontrolled hypertension
• Known history of porphyria, G6PD deficiency, HIV

Where it is running

• Study site — San Diego, California, United States
• Study site — Stanford, California, United States
• Study site — Miami, Florida, United States
• Study site — Chicago, Illinois, United States
• Study site — Baltimore, Maryland, United States
• Study site — Rochester, Minnesota, United States
• Study site — Madison, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.